Abstract
Results During the follow-up, 48 patients (35.6%) had a local recurrence of the tumor. Patients with local recurrence had a higher level of PIM-1 expression than those who achieved local control of the disease (P=0.017). Five-year local recurrencefree survival for patients with a high expression of PIM-1 (n=43) was 44.6% (95% CI 29.2-60.0%), and for patients with low expression (n=92) it was 71.9% (95% CI 62.5-81.3%) (P=0.007). According to the results of multivariate analysis, patients with a high PIM-1 expression had a 2.2-fold increased risk of local recurrence (95% CI 1.22-4.10, P=0.009). Conclusion Patients with elevated transcriptional expression levels of PIM-1 had a signifcantly higher risk of local recurrence after radiotherapy.
Original language | English |
---|---|
Pages (from-to) | 3679–3684 |
Number of pages | 6 |
Journal | European Archives of Oto-Rhino-Laryngology |
Volume | 279 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- PIM-1
- Head and neck carcinoma
- Radiotherapy
- Local control
- Biomarker